Stock Traders Buy Large Volume of Put Options on Maravai LifeSciences (NASDAQ:MRVI)

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) was the recipient of some unusual options trading on Wednesday. Investors purchased 1,002 put options on the stock. This represents an increase of 1,791% compared to the typical volume of 53 put options.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MRVI. Baird R W downgraded Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. UBS Group cut their target price on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday, March 21st. Craig Hallum cut their target price on shares of Maravai LifeSciences from $12.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday. Robert W. Baird cut their target price on shares of Maravai LifeSciences from $3.00 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday. Finally, Morgan Stanley cut their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an "equal weight" rating on the stock in a report on Tuesday, March 25th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $6.64.

Institutional Investors Weigh In On Maravai LifeSciences

Large investors have recently bought and sold shares of the company. Performa Ltd US LLC increased its position in shares of Maravai LifeSciences by 614.3% during the fourth quarter. Performa Ltd US LLC now owns 5,000 shares of the company's stock worth $27,000 after acquiring an additional 4,300 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Maravai LifeSciences during the first quarter worth $32,000. Teacher Retirement System of Texas acquired a new position in Maravai LifeSciences during the first quarter worth $37,000. Aigen Investment Management LP acquired a new position in Maravai LifeSciences during the first quarter worth $37,000. Finally, FNY Investment Advisers LLC boosted its holdings in Maravai LifeSciences by 600.0% during the fourth quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company's stock worth $38,000 after purchasing an additional 6,000 shares during the last quarter. Institutional investors own 50.25% of the company's stock.

Maravai LifeSciences Stock Down 3.9%

MRVI stock opened at $1.98 on Thursday. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89. Maravai LifeSciences has a 1 year low of $1.67 and a 1 year high of $11.56. The company has a fifty day simple moving average of $2.12 and a 200 day simple moving average of $4.13. The firm has a market cap of $503.59 million, a PE ratio of -1.21 and a beta of 0.19.

Maravai LifeSciences (NASDAQ:MRVI - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). Maravai LifeSciences had a negative net margin of 81.13% and a negative return on equity of 6.61%. The business had revenue of $46.85 million for the quarter, compared to analyst estimates of $44.01 million. The company's quarterly revenue was down 26.9% on a year-over-year basis. Sell-side analysts anticipate that Maravai LifeSciences will post -0.24 EPS for the current fiscal year.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.